FY2024 Earnings Estimate for VIRX Issued By Leerink Partnrs

Viracta Therapeutics, Inc. (NASDAQ:VIRX) – Stock analysts at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Viracta Therapeutics in a report issued on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.80) per share for the year, down from their previous forecast of ($0.69). The consensus estimate for Viracta Therapeutics’ current full-year earnings is ($0.80) per share. Leerink Partnrs also issued estimates for Viracta Therapeutics’ Q4 2024 earnings at ($0.13) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.40) EPS.

VIRX has been the subject of several other reports. Leerink Partners downgraded Viracta Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $5.00 to $3.00 in a research note on Friday, August 16th. Royal Bank of Canada decreased their price target on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th.

Viracta Therapeutics Stock Performance

NASDAQ:VIRX opened at $0.15 on Monday. The firm has a fifty day simple moving average of $0.22 and a two-hundred day simple moving average of $0.42. Viracta Therapeutics has a 12 month low of $0.13 and a 12 month high of $1.31. The stock has a market capitalization of $6.08 million, a price-to-earnings ratio of -0.14 and a beta of 0.72.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Viracta Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned about 1.27% of Viracta Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.